Diker O - Search Results

1

When side effect becomes the effect: Efficacy of capecitabine in refractory psoriasis.

Karakas Y, Vural S, Diker O, Dizdar O. Karakas Y, et al. Among authors: diker o. Dermatol Ther. 2018 Nov;31(6):e12629. doi: 10.1111/dth.12629. Epub 2018 Sep 19. Dermatol Ther. 2018. PMID: 30230162 No abstract available.

2

Development of a Novel Predictive-Prognostic Scoring Index for Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer.

Diker O, Olgun P, Balyemez U, Sigit Ikiz S. Diker O, et al. Cureus. 2023 Jan 1;15(1):e33234. doi: 10.7759/cureus.33234. eCollection 2023 Jan. Cureus. 2023. PMID: 36733552 Free PMC article.

3

Chemotherapy might not be beneficial in lymph node- negative, hormone-positive, and HER2-negative breast cancer patients: a long-term retrospective analysis.

Babacan T, Buyukhatipoglu H, Balakan O, Kertmen N, Suner A, Sarici F, Akin S, Ates O, Karakas Y, Aslan A, Diker O, Altundag K. Babacan T, et al. Among authors: diker o. J BUON. 2015 Mar-Apr;20(2):479-86. J BUON. 2015. PMID: 26011339 Free article.

4

Correlation of educational status and clinicopathological characteristics of breast cancer: a single center experience.

Sarici F, Babacan T, Buyukhatipoglu H, Balakan O, Sever AR, Kertmen N, Unlu O, Ates O, Diker O, Akin S, Sunar V, Karakas Y, Lacin S, Altundag K. Sarici F, et al. Among authors: diker o. J BUON. 2016 Jul-Aug;21(4):826-831. J BUON. 2016. PMID: 27685902 Free article.

5

Adjuvant treatment with paclitaxel plus trastuzumab for node-negative breast cancer: real-life experience.

Diker O, Aktas BY, Ak R, Koylu B, Bas O, Taban H, Guven DC, Olgun P, Kertmen N, Dizdar O, Oksuzoglu B, Aksoy S. Diker O, et al. Future Oncol. 2022 Jan;18(3):323-331. doi: 10.2217/fon-2021-0303. Epub 2021 Nov 11. Future Oncol. 2022. PMID: 34758639

6

A retrospective analysis of adjuvant CAF, AC-T and TAC regimens in triple negative early stage breast cancer.

Buyukhatipoglu H, Babacan T, Kertmen N, Balakan O, Suner A, Ates O, Sarici F, Aslan A, Diker O, Tasdemir V, Ozisik Y, Altundag K. Buyukhatipoglu H, et al. Among authors: diker o. J BUON. 2015 Jan-Feb;20(1):22-7. J BUON. 2015. PMID: 25778291 Free article.

7

Atezolizumab plus Chemotherapy in Small-Cell Lung Cancer.

Diker O. Diker O. N Engl J Med. 2019 Feb 28;380(9):889. doi: 10.1056/NEJMc1900123. N Engl J Med. 2019. PMID: 30811921 No abstract available.

8

First-line pembrolizumab efficacy in patients with advanced non-small cell lung cancer: A Bi-center retrospective, real-life experience study.

Diker O, Olgun P. Diker O, et al. J BUON. 2021 May-Jun;26(3):844-852. J BUON. 2021. PMID: 34268944 Free article.

9

Salvage chemotherapy in patients with nonsmall cell lung cancer after prior immunotherapy: a retrospective, real-life experience study.

Diker O, Olgun P. Diker O, et al. Anticancer Drugs. 2022 Sep 1;33(8):752-757. doi: 10.1097/CAD.0000000000001330. Epub 2022 Aug 10. Anticancer Drugs. 2022. PMID: 35946540

10

The role of the pharmacist in the multidisciplinary approach to the prevention and resolution of drug-related problems in cancer chemotherapy.

Boşnak AS, Birand N, Diker Ö, Abdi A, Başgut B. Boşnak AS, et al. Among authors: diker o. J Oncol Pharm Pract. 2019 Sep;25(6):1312-1320. doi: 10.1177/1078155218786048. Epub 2018 Jul 9. J Oncol Pharm Pract. 2019. PMID: 29984626

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

19 results

Search Page

Filters